Our case involved a patient with ALK-positive advanced lung adenocarcinoma that underwent a small cell lung cancer transformation after treatment with a first-generation ALK-TKI (crizotinib) and response to second-generation ALK-TKI (alectinib), followed by drug resistance caused by a secondary mutation in the ALK kinase domain. The gene discussed is ALK; the disease is lung adenocarcinoma.